- LEARNING CENTERS
- Your GRU
- Log In / Log Out
Section Editor: R. Jonathan Henderson, MD
Latest prostate cancer research is turning its focus on the M0 space. M0 prostate cancer is a stage where the disease is non-metastatic but has become resistant to hormone therapy. Many therapeutic options for castration-resistant prostate cancer are approved and used for metastatic castration-resistant prostate cancer (mCRPC), but fewer options exist for those with non-metastatic (NM) CRPC.
Eric J. Small, MD, FASCO, defines nonmetastatic castration-resistant prostate cancer, or M0 disease. He then discusses the design, implementation, and results of the SPARTAN trial, which he presented at the 2018 Genitourinary Cancers Symposium. The study tested the efficacy of apalutamide in men with M0 disease.
Jonathan Henderson, MD, obtained a Bachelor of Science Degree at LSU in Baton Rouge in microbiology. After receiving his M.D. at LSU Medical Center in Shreveport, he completed his internship and residency in Urology at LSUMC Hospital. During this time, he authored a number of papers and presentations. Dr. Henderson spent the next six years in practice in Alabama where he specialized in treating disorders of the female bladder and laparoscopy. During this time, he served as a representative of Alabama to the Southeastern Section of the American Urology Association. He also served as an assistant clinical professor of Urology at the University of Alabama. Dr. Henderson is certified by the American Board of Urology. He is a member of the American Urologic Association, Shreveport Medical Society, Louisiana State Medical Society, the Society of Laparoscopic Surgeons, and the Alpha Omega Alpha Medical Honor Society. He has been on the LUGPA Board of Directors since 2011 and is currently serving as Secretary.